Sanofi (SNY) and Lannett Co (LCI) Financial Contrast
Sanofi (NYSE: SNY) and Lannett Co (NYSE:LCI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.
Valuation & Earnings
This table compares Sanofi and Lannett Co’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Sanofi||$42.52 billion||2.85||$12.76 billion||$3.92||12.29|
|Lannett Co||$637.34 million||1.03||$247.01 million||($0.03)||-586.47|
Sanofi has higher revenue and earnings than Lannett Co. Lannett Co is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
9.3% of Sanofi shares are owned by institutional investors. Comparatively, 88.1% of Lannett Co shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 15.0% of Lannett Co shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Sanofi has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Lannett Co has a beta of 2.7, meaning that its stock price is 170% more volatile than the S&P 500.
This table compares Sanofi and Lannett Co’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Sanofi pays an annual dividend of $1.10 per share and has a dividend yield of 2.3%. Lannett Co does not pay a dividend. Sanofi pays out 28.1% of its earnings in the form of a dividend.
This is a breakdown of recent recommendations and price targets for Sanofi and Lannett Co, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sanofi presently has a consensus price target of $53.50, suggesting a potential upside of 11.02%. Lannett Co has a consensus price target of $21.00, suggesting a potential upside of 19.32%. Given Lannett Co’s stronger consensus rating and higher probable upside, analysts plainly believe Lannett Co is more favorable than Sanofi.
Sanofi beats Lannett Co on 9 of the 15 factors compared between the two stocks.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company’s vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company’s vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.
Lannett Co Company Profile
Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.